Olivier Kosmider
Overview
Explore the profile of Olivier Kosmider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
4368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao L, Jachiet V, Kosmider O, Larcher L, Clappier E, Sebert M, et al.
Haematologica
. 2025 Jan;
PMID: 39882650
Not available.
2.
Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf A, Smith A, et al.
Hemasphere
. 2025 Jan;
9(1):e70073.
PMID: 39850648
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent...
3.
Mathurin M, Hirsch P, Jachiet V, Hadjadj J, Le Guenno G, Heiblig M, et al.
Kidney Int Rep
. 2025 Jan;
10(1):260-264.
PMID: 39810778
No abstract available.
4.
Tiso F, In t Hout F, Knops R, Kroeze L, van Rooij A, van de Loosdrecht A, et al.
Hemasphere
. 2025 Jan;
9(1):e70034.
PMID: 39760001
No abstract available.
5.
Barbosa Bomfim C, Genin H, Cottoignies-Callamarte A, Gallois-Montbrun S, Murigneux E, Sams A, et al.
J Virol
. 2024 Dec;
99(1):e0200624.
PMID: 39655958
No abstract available.
6.
Debureaux P, Poulain S, Harel S, Passet M, Temple M, Friedrich C, et al.
Blood
. 2024 Nov;
145(4):450-454.
PMID: 39571148
Inflammatory form of Waldenström macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and Bruton tyrosine kinase inhibitors, but its origin is unknown. Here, we unravel increased clonal hematopoiesis in patients with iWM...
7.
Heiblig M, Gourguechon C, Guilpain P, Bulai-Livideanu C, Barete S, Chantran Y, et al.
Am J Hematol
. 2024 Sep;
99(11):2127-2139.
PMID: 39287048
Advanced systemic mastocytosis (AdvSM) encompasses heterogeneous mastocytosis subtypes and is associated with poor outcomes. Although midostaurin was the first tyrosine kinase inhibitor to be approved for AdvSM patients, long-lasting responses...
8.
De Almeida Braga C, Bauvais M, Sujobert P, Heiblig M, Jullien M, Le Calvez B, et al.
Int J Lab Hematol
. 2024 Sep;
47(1):120-129.
PMID: 39275905
Introduction: VEXAS is a syndrome described in 2020, caused by mutations of the UBA1 gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack...
9.
Raddi M, Bencini S, Peruzzi B, Mattiuz G, De Pourcq S, Tanturli M, et al.
Blood Cancer J
. 2024 Aug;
14(1):127.
PMID: 39112451
No abstract available.
10.
Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, et al.
Sci Transl Med
. 2024 Jul;
16(757):eadk1731.
PMID: 39047119
Acute myeloid leukemia (AML) remains a challenging hematological malignancy with poor prognosis and limited treatment options. Leukemic stem cells (LSCs) contribute to therapeutic failure, relapse, and adverse outcome. This study...